Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
26 hedge funds and large institutions have $11.7M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 1
503% more capital invested
Capital invested by funds: $1.93M → $11.7M (+$9.72M)
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
63% more funds holding
Funds holding: 16 → 26 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.22M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.3M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
+$1.04M |
| 4 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
+$816K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$758K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$68.4K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$65.5K |
| 3 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$18.8K |
| 4 |
RA
Royce & Associates
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$65.5K | -3,783 | -100% |
|
|
RA
27
Royce & Associates
New York
| – | -$6K | -431 | Closed |
|
OPNT Hedge Fund Activity: Q3 2018 in Review
26 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q3 2018, worth a combined $11.7M — up 503% from $1.93M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OPNT positions and 1 closed out — a net gain of 10 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.22M. The largest seller was Acadian Asset Management, cutting an estimated $68.4K.
- 26 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q3 2018, up from 16 in Q2 2018.
- Funds reported $11.7M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q3 2018, up 503% quarter-over-quarter.
- 11 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 1 closed out, a net change of +10 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was Stonepine Capital Management, an estimated $3.22M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Acadian Asset Management, an estimated $68.4K sold.
Based on aggregated 13F filings for Q3 2018.